ARCH Venture Partners XII, LLC

Insider Reports History

Location
8755 W Higgins Road, Suite 1025, Chicago, IL
Signature
ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by ARCH Venture Partners XII, LLC:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Rapport Therapeutics, Inc. 10%+ Owner Common Stock 3.73M $37.2M $9.98 Jun 10, 2024 By ARCH Venture Fund XII, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 12.2M $22.2M $1.82 Oct 27, 2025 By ARCH Venture Fund X, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 11.9M $21.6M $1.82 Oct 27, 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 6.05M $15.8M $2.61 Oct 27, 2025 By ARCH Venture Fund XII, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6.23M $7.91M $1.27 Aug 1, 2025 By ARCH Venture Fund XII, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6.13M $7.78M $1.27 Aug 1, 2025 By ARCH Venture Fund X, L.P.
Prime Medicine, Inc. 10%+ Owner Common Stock 6.13M $7.78M $1.27 Aug 1, 2025 By ARCH Venture Fund X Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 2.32M $4.23M $1.82 Oct 27, 2025 By ARCH Venture Fund VIII Overage, L.P.
Neumora Therapeutics, Inc. 10%+ Owner Common Stock 1.39M $2.52M $1.82 Oct 27, 2025 By ARCH Venture Fund VII, L.P.
Metsera, Inc. Director, 10%+ Owner Common Stock 0 $0 $52.33 Nov 13, 2025 Indirect
Metsera, Inc. Director, 10%+ Owner Series A Convertible Preferred Stock 0 Feb 3, 2025 Indirect
Metsera, Inc. Director, 10%+ Owner Series B Convertible Preferred Stock 0 Feb 3, 2025 Indirect
Metsera, Inc. Director, 10%+ Owner Series Seed Preferred Stock 0 Feb 3, 2025 Indirect
Rapport Therapeutics, Inc. 10%+ Owner Series A Preferred Stock 0 Jun 10, 2024 By ARCH Venture Fund XII, L.P.
Rapport Therapeutics, Inc. 10%+ Owner Series B Preferred Stock 0 Jun 10, 2024 By ARCH Venture Fund XII, L.P.

Insider Reports Filed by ARCH Venture Partners XII, LLC

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MTSR Metsera, Inc. Nov 13, 2025 2 $0 4 Nov 14, 2025 Director, 10%+ Owner
NMRA Neumora Therapeutics, Inc. Oct 27, 2025 1 $5M 4 Oct 29, 2025 10%+ Owner
PRME Prime Medicine, Inc. Aug 1, 2025 1 $10M 4 Aug 1, 2025 10%+ Owner
MTSR Metsera, Inc. Feb 3, 2025 9 $40M 4 Feb 3, 2025 10%+ Owner
MTSR Metsera, Inc. Jan 30, 2025 0 $0 3 Jan 30, 2025 10%+ Owner
RAPP Rapport Therapeutics, Inc. Jun 10, 2024 3 $0 4 Jun 10, 2024 10%+ Owner
RAPP Rapport Therapeutics, Inc. Jun 6, 2024 0 $0 3 Jun 6, 2024 10%+ Owner
PRME Prime Medicine, Inc. Feb 15, 2024 1 $20M 4 Feb 20, 2024 10%+ Owner
NMRA Neumora Therapeutics, Inc. Dec 8, 2023 2 $0 4 Dec 12, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Nov 13, 2023 2 $412K 4 Nov 15, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Nov 8, 2023 5 $1.54M 4 Nov 13, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Nov 3, 2023 3 $1.1M 4 Nov 7, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 28, 2023 3 $1.05M 4 Sep 29, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 26, 2023 2 $700K 4 Sep 27, 2023 10%+ Owner
NMRA Neumora Therapeutics, Inc. Sep 22, 2023 3 $1.13M 4 Sep 25, 2023 10%+ Owner